Outcomes of Patients Who Are BCMA (B-cell maturation Antigen) Directed Therapy (BDT) Exposed Vs BCMA Naive in Penta-Relapsed Refractory Multiple Myeloma (RRMM)

被引：1

作者：

Mammadzadeh, Aytaj ^{[1
]}

Peng, Fulei ^{[2
]}

Atrash, Shebli ^{[3
,4
]}

Hashmi, Hamza ^{[3
,5
]}

Mohan, Meera ^{[3
,6
]}

Alkharabsheh, Omar ^{[3
,7
]}

Afrough, Aimaz ^{[3
,8
]}

Cui, Wei ^{[3
,9
]}

Mahmoudjafari, Zahra ^{[3
,10
]}

Abdallah, Al-Ola ^{[11
,12
]}

机构：

[1] Azerbaijan Med Univ, Dept Internal Med, Baku, Azerbaijan

[2] Mercy St Louis Hosp, Dept Internal Med, St Louis, MO USA

[3] US Myeloma Res Innovat Res Collaborat USMIRC, Westwood, KS USA

[4] Atrium Hlth, Levine Canc Inst, Dept Hematol Oncol & Blood Disorders, Charlotte, NC USA

[5] Med Univ South Carolina, Dept Hematol Med Oncol, Charleston, SC 29425 USA

[6] Med Coll Wisconsin, Milwaukee, WI 53226 USA

[7] Univ S Alabama, Mitchell Canc Inst, Div Hematol Oncol, Mobile, AL USA

[8] UT Southwestern Med Ctr, Div Hematol Malignancies & Cellular Therapy, Dept Internal Med, Harold C Simmons Comprehens Canc Ctr, Dallas, TX USA

[9] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA

[10] Univ Kansas, Med Ctr, Div Hematol Malignancies & Cellular Therapeut, Kansas City, KS 66103 USA

[11] Univ Kansas, Med Ctr, Div Hematol Malignancies & Cellular Therapeut, Westwood, KS USA

[12] US Myeloma Innovat Res Collaborat USMIRC, Westwood, KS USA

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-165762

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：4277 / 4278

页数：2

共 50 条

[31] B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches
Shah, Nina
Chari, Ajai
Scott, Emma
Mezzi, Khalid
Usmani, Saad Z.
LEUKEMIA, 2020, 34 (04) : 985 - 1005
[32] B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches
Nina Shah
Ajai Chari
Emma Scott
Khalid Mezzi
Saad Z. Usmani
Leukemia, 2020, 34 : 985 - 1005
[33] Safety and Efficacy of B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells (CART-BCMA) with Cyclophosphamide Conditioning for Refractory Multiple Myeloma (MM)
Cohen, Adam D.
Garfall, Alfred L.
Stadtmauer, Edward A.
Lacey, Simon F.
Lancaster, Eric
Vogl, Dan T.
Weiss, Brendan M.
Ambrose, David E.
Nelson, Anne Marie
Chen, Fang
Plesa, Gabriela
Kulikovskaya, Irina
Gonzalez, Vanessa
Gupta, Minnal
Young, Regina M.
Dengel, Karen
O'keefe, Laura
Le, Samantha
Richardson, Celeste
Isaacs, Randi E.
Melenhorst, J. Joseph
Levine, Bruce L.
June, Carl H.
Milone, Michael C.
BLOOD, 2017, 130
[34] A Novel Composite Endpoint of Toxicity- and Progression-Free Survival after B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma
Mohty, Razan
Junmin, Whiting
Saha, Aditi
Kim, Jongphil
Nishihori, Taiga
De Avila, Gabriel
Corallo, Salvatore
Dam, Marian
Marin, Jessica
Liu, Hien
Mokhtari, Sepideh
Jain, Michael D.
Perna, Fabiana
Blue, Brandon
Grajales-Cruz, Ariel F.
Castaneda, Omar
Shain, Kenneth
Baz, Rachid
Freeman, Ciara Louise L.
Alsina, Melissa
Locke, Frederick L.
Hansen, Doris K.
Lazaryan, Aleksandr
BLOOD, 2023, 142
[35] Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): Updated efficacy and safety results from MajesTEC-1.
Nooka, Ajay K.
Moreau, Philippe
Usmani, Saad Zafar
Garfall, Alfred L.
Van De Donk, Niels W. C. J.
San-Miguel, Jesus F.
Oriol Rocafiguera, Albert
Chari, Ajai
Karlin, Lionel
Mateos, Maria-Victoria
Popat, Rakesh
Martinez, Joaquin
Sidana, Surbhi
Trancucci, Danielle
Verona, Raluca
Girgis, Suzette
Uhlar, Clarissa
Stephenson, Tara
Banerjee, Arnob
Krishnan, Amrita Y.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[36] Clinical Outcome of Patients with Relapsed Refractory Multiple Myeloma Listed for BCMA Directed Commercial CAR T Therapy
Al Hadidi, Samer
Szabo, Aniko
Esselmann, Jean
Hammons, Lindsay
Hussain, Munawwar
Ogunsesan, Yetunde
Thalambedu, Nishanth
Khan, Fatima
Sethi, Jaskirat
Janardan, Abhishek
Radhakrishnan, Sabarinath
Thanendrarajan, Sharmilan
Schinke, Carolina
Dhakal, Binod
Janz, Siegfried
Chhabra, Saurabh
D'Souza, Anita
Zangari, Maurizio
van Rhee, Frits
Mohan, Meera
BLOOD, 2022, 140 : 8038 - 8039
[37] Ciltacabtagene autoleucel CAR-T therapy targeting B-cell maturation antigen (BCMA) Treatment of multiple myeloma
Lee, Sarah
Cowan, Andrew J.
DRUGS OF THE FUTURE, 2022, 47 (04) : 233 - 238
[38] Focus on monoclonal antibodies targeting B-cell maturation antigen (BCMA) in multiple myeloma: update 2020
Demel, Ivo
Bago, Julio Rodriguez
Hajek, Roman
Jelinek, Tomas
BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 (04) : 705 - 722
[39] POPULATION PHARM ACOKINETICS (POPPK) OF ABBV-383, A B-CELL MATURATION ANTIGEN (BCMA) x CD3 BISPECIFIC T-CELL-REDIRECTING ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
Polepally, A.
Badillo, J.
Rinas, M.
Ahsan, A.
Bueno, O.
Talati, C.
Menon, R.
Engelhardt, B.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S69 - S69
[40] Preliminary Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Subcutaneously (SC) Administered PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Lesokhin, Alexander M.
Levy, Moshe Y.
Dalovisio, Andrew P.
Bahlis, Nizar J.
Solh, Melhem
Sebag, Michael
Jakubowiak, Andrzej
Jethava, Yogesh S.
Costello, Caitlin L.
Chu, Michael P.
Savona, Michael R.
Gasparetto, Cristina
Trudel, Suzanne
Chou, Jeffrey
Udata, Chandrasekhar
Basu, Cynthia
Krupka, Heike I.
Raje, Noopur S.
BLOOD, 2020, 136

← 1 2 3 4 5 →